Real‐world outcomes with immunosuppressive therapy for aplastic anemia in patients treated at the University of Michigan

• Published in: European journal of haematology Vol. 112; no. 3; pp. 424 - 432
• Main Authors: Foucar, Charles E., Foley, Daniel H., Aldous, Jessica, Burke, Patrick W., Pettit, Kristen R., Benitez, Lydia L., Perissinotti, Anthony J., Marini, Bernard L., Boonstra, Philip, Bixby, Dale L.
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.03.2024
• Subjects: Aged; Allografts; Anemia; Anemia, Aplastic - diagnosis; Anemia, Aplastic - drug therapy; Antilymphocyte serum; Antilymphocyte Serum - adverse effects; Aplastic anemia; Benzoates; Comorbidity; Cyclosporine - adverse effects; Cyclosporins; elderly; eltrombopag; Globulins; Humans; Hydrazines; Immunological tolerance; Immunosuppression Therapy; Immunosuppressive agents; Immunosuppressive Agents - adverse effects; immunosuppressive therapy; Middle Aged; Pyrazoles; Statistical analysis; Stem cell transplantation; Thymocytes; Treatment Outcome; immunosuppressive therapy; aplastic anemia; eltrombopag; elderly
• ISSN: 0902-4441; 1600-0609
• DOI: 10.1111/ejh.14131

Aplastic anemia (AA) is a rare bone marrow failure disorder that is treated with either allogeneic stem cell transplant or immunosuppressive therapy (IST) consisting of antithymocyte globulin (ATG), cyclosporine (CSA), and eltrombopag. While outcomes are favorable in younger patients, older patients (>60) have significantly worse long‐term survival. The dose of ATG is often reduced in older patients and those with multiple comorbidities given concerns for tolerability. The efficacy and safety of dose‐attenuated IST in this population is largely undescribed. We performed a retrospective review of patients with AA treated with IST. Our analysis was confounded by changes in practice patterns and the introduction of eltrombopag. We identified 53 patients >60 years old, of which, 20 received dose‐attenuated IST, with no statistically significant difference in overall survival between full and attenuated dose cohorts. Overall response rates in both cohorts were similar at 6 months at 71% and 68%. There were more documented infectious complications in the full dose cohort (13 vs. 3). This supports the consideration of dose‐attenuated IST in older patients with concerns about tolerance of IST. Lastly, our data confirmed favorable outcomes of younger patients receiving IST, especially in combination with eltrombopag.